Metropolis Healthcare Ltd Q2 FY2025 Concall Summary

Key Takeaways

• Steady 13.4% revenue growth, B2C leads: Revenue grew 13.4% YoY, within the guided 13-15% band, driven by 21% B2C growth while B2B improved to 13% from single digits.
• Margin choice, not margin problem: EBITDA margin is suppressed by deliberate investment in ~90 new labs since FY21, a 50%+ capacity increase; management states 100-200 bps of expansion is "within our control at any point."
• Network build-out nearing completion: The mega lab expansion cycle largely ends this year, with lab additions dropping from 25/year to 4-5/year from FY26, setting up an operating leverage tailwind.
• Government disengagement a deliberate drag: Strategic exit from low-margin institutional business shaved growth for two quarters and may continue for another two, masking underlying volume momentum.
• What to watch next quarter: Whether the guided margin recovery toward 26-27% begins as the FY24/25 lab tranche matures, and if B2C volume growth sustains above 12% as the price-hike effect fades.

B2C Engine: Volume, Mix and the TruHealth Flywheel

• Patient volume driving the top line: B2C patient volume grew 12% YoY, with revenue per test up 5% from product mix improvement, not just price hikes.
• TruHealth pulling two levers at once: Wellness packages grew 26% and now contribute 16% of revenue, with a stated target of 20% in coming quarters; because more tests per patient require no additional sample collection, incremental tests flow through at high marginal EBITDA.
• Sample-per-patient improving: The metric moved from 2.2-2.3 to 2.7-2.8 as TruHealth and specialty mix improves, a structural uplift in revenue per patient visit.
• Specialty as a moat: Specialty testing grew 24% within B2C, supported by new test launches in oncology, transplant panels, and pre-IVF genetic testing; the 4,000-test menu vs ~100 at independent centers creates a widening gap.
• Digital engines now live: A recommendation engine at the point of collection, upgraded app and website, and a customer data platform for programmed re-engagement are all operational, aiming to lift tests per patient and repeat visits.

Ameera Shah: "Independent centers typically offer a limited range of tests with an average of around 100 tests compared to over the 4,000 varieties of tests that are available at Metropolis."

Network Expansion: The End of the Investment Cycle

• The big build is nearly done: Metropolis added ~90 labs from FY21 through FY25, increasing capacity over 50%; by the end of this year, the objective is largely met, with only 8-10 more labs expected in the coming year.
• Lab additions dropping sharply: Targeting 25 new labs in FY25, then down to 4-5 per year from FY26, a step-change reduction in expansion-related expenditure.
• Center expansion shifts asset-light: Targeting ~500 collection center additions this year; from FY26, center expansion accelerates but through the franchisee route (~400/year), limiting capital dilution.
• Town footprint doubling: Entered 400+ new towns in 24 months, reaching nearly 700 towns, with a target of 1,000 towns in the next 12-18 months, concentrated in Tier 3/4 markets where specialist doctors are returning to set up hospitals.
• Lab consolidation underway: 14-odd labs consolidated in H1 (net addition of 3 vs 17 gross) where synergies existed between Metropolis and Hitech, or where a lab was not viable, done without revenue or customer experience impact.

Margin Trajectory: Investment Math, Not Structural Decline

• The post-COVID choice: Pre-COVID industry margins were ~26%, spiked to 28-29% during COVID; management chose to reinvest the windfall into lab expansion rather than let operating leverage flow to profit, a trade-off it says peers did not make.
• New lab margin drag quantified: New labs run at roughly minus 10% EBITDA in year one, turn single-digit positive in year two, and approach company margins by month 30; the FY22 tranche is now margin-positive, while FY24 and FY25 additions are the current weight.
• The 1.2% EBITDA impact: New labs and centers currently impose a ~1.2% EBITDA headwind that management expects to "start settling in the next couple of years" as these assets mature.
• Medium-term margin guide: 26-27% EBITDA margin over the next 2-3 years, with management asserting the business has capability to expand toward 28-29% but prefers to keep reinvesting; "any time they want to turn a knob they can release further margin."
• Geography matters for payback: New labs in West and South mature faster than those in North and East, where the brand is still being built.

Ameera Shah: "The choice we had post COVID was, as some of the peers have done is not really invest in lab expansion or other areas, but to actually let the operating leverage flow through to the profit. But that very clearly then reflects in a much smaller growth in volume, patient volume, test volume as well as in revenue growth. The choice that we chose to make is that considering the large opportunity in India at hand, we felt that rather than maximizing margins, that we believe that the opportunity really stood in continuing to increase access and to continue to grow across the country."

B2B and the Institutional Reset

• B2B growth revived: B2B revenue growth reached 13% in the last two quarters, up from single digits, driven by focused client engagement, enhanced experience programs, and discount discipline that kept pricing steady while lifting productivity per client.
• Government exit still a headwind: Strategic disengagement from government and institutional clients reduced that segment from 10% to 7-8% of revenue, and the decline may continue for another couple of quarters, suppressing overall growth by an undisclosed amount.
• The hospital mix is fragmented: 85-90% of hospital business comes from smaller, unorganized hospitals, not listed chains; larger B2B customers are drawn from this unorganized segment, insulating Metropolis from the pricing conflicts that hospital chains face between in-house and external diagnostics.
• South region temporarily muted: A couple of institutional disengagements in the South held back growth there; management expects the region to "join the party" going forward.

Competitive Moat: Why Fragmentation Favors the Organized

• The 85% unorganized market is struggling: Independent centers face volume decline as organized chains enter micro-markets; they lack the test menu breadth, brand, and talent to compete, and most city-focused businesses have not scaled profitably.
• Hospital chains face a pricing trap: Retail prices outside hospitals are one-third of in-house charges, creating customer conflict and cannibalization that limits their diagnostics ambition to a few geographies like Delhi and Hyderabad.
• Regional labs hit a scaling wall: Capital is available but the ability to build brand, attract talent, deliver consistent quality, and construct a complex test menu are the real barriers; "most city-focused businesses have not been able to scale and definitely not scale profitably."
• New-age e-health players forced into brick-and-mortar: Tech-enabled competitors have struggled to generate illness-driven volumes and raised prices to improve unit economics, compelling them to enter the physical lab model, which is long and challenging to scale profitably.
• Tier 3/4 as a two-decade tailwind: Specialist doctors migrating back to hometowns and setting up hospitals in smaller cities increases local diagnostics demand; Metropolis pre-positioned labs in these markets over the last four years and expects the trend to continue for at least 20 years.

Ameera Shah: "While capital is available to expand, the ability to build brand, attract talent and management expertise to provide quality and quick results across regions consistently and build a complex test menu that are needed to scale the business are actually the mopes of our industry when you're building a chain, which is why most city-focused businesses have not been able to scale and definitely not scale profitably."

Inorganic Strategy and Adjacencies

• M&A pipeline active but highly selective: Management is in advanced stages of evaluating targets but states 90-95% of available assets are not investable due to poor governance or business models; the filter is for high-quality businesses that can generate fair profits over time.
• Acquisition archetypes defined: Bolt-on targets must have majority B2C revenue yielding high margins; B2B acquisitions must be non-commoditized, high-specialty businesses; sizes can range from small city leaders to larger regional or pan-India players, with fair pricing judged from a ROCE perspective.
• Track record cited: 20-odd deals integrated over 20 years; management emphasizes fair valuation at entry and execution capability as the keys to driving good ROI.
• Adjacencies in pilot: Experimenting with consultations and other models in 500 owned-and-operated centers; basic radiology already added in many centers, testing the bundling opportunity.

Guidance & Commitments

Key Metrics